Human Pluripotent Stem Cells for High-Throughput Drug Screening and Characterization of Small Molecules.

Cell viability Dose–response curves Embryonic stem cells High-throughput screening Induced pluripotent stem cells Robotic cell culture Small molecules Toxicity

Journal

Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969

Informations de publication

Date de publication:
2022
Historique:
pubmed: 16 6 2021
medline: 24 6 2022
entrez: 15 6 2021
Statut: ppublish

Résumé

Human pluripotent stem cells (hPSCs), such as induced pluripotent stem cells (iPSCs), hold great promise for drug discovery, toxicology studies, and regenerative medicine. Here, we describe standardized protocols and experimental procedures that combine automated cell culture for scalable production of hPSCs with quantitative high-throughput screening (qHTS) in miniaturized 384-well plates. As a proof of principle, we established dose-response assessments and determined optimal concentrations of 12 small molecule compounds that are commonly used in the stem cell field. Multi-parametric analysis of readouts from diverse assays including cell viability, mitochondrial membrane potential, plasma membrane integrity, and ATP production was used to distinguish normal biological responses from cellular stress induced by small molecule treatment. Collectively, the establishment of integrated workflows for cell manufacturing, qHTS, high-content imaging, and data analysis provides an end-to-end platform for industrial-scale projects and should leverage the drug discovery process using hPSC-derived cell types.

Identifiants

pubmed: 34128205
doi: 10.1007/7651_2021_394
pmc: PMC9520585
mid: NIHMS1831765
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

811-827

Subventions

Organisme : Intramural NIH HHS
ID : Z99 TR999999
Pays : United States

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2021. Springer Science+Business Media, LLC.

Références

Nat Biotechnol. 2009 Mar;27(3):275-80
pubmed: 19252484
Cell Stem Cell. 2020 Mar 5;26(3):309-329
pubmed: 32142662
Methods Mol Biol. 2016;1473:17-22
pubmed: 27518619
J Cell Sci. 2005 Oct 1;118(Pt 19):4495-509
pubmed: 16179608
Nat Methods. 2021 May;18(5):528-541
pubmed: 33941937
Mol Cell. 2017 May 4;66(3):306-319
pubmed: 28475867
Methods Mol Biol. 2011;740:1-6
pubmed: 21468961
J Cell Sci. 2004 Mar 1;117(Pt 7):1269-80
pubmed: 14996946
Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):12538-43
pubmed: 22802639
Nat Rev Drug Discov. 2017 Feb;16(2):115-130
pubmed: 27980341
Stem Cell Reports. 2016 Sep 13;7(3):527-542
pubmed: 27569059
Stem Cells. 2018 Oct;36(10):1501-1513
pubmed: 29873142
Nat Rev Drug Discov. 2020 Jul;19(7):463-479
pubmed: 32612263
PLoS One. 2008 Aug 06;3(8):e2904
pubmed: 18682835
Methods Mol Biol. 2011;740:103-14
pubmed: 21468972
Nat Biotechnol. 2015 Nov;33(11):1173-81
pubmed: 26501951
Stem Cell Reports. 2021 Dec 14;16(12):3076-3092
pubmed: 34861164
Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11473-8
pubmed: 16864780
Nat Methods. 2005 Mar;2(3):185-90
pubmed: 15782187
Cell Stem Cell. 2020 Oct 1;27(4):523-531
pubmed: 33007237
Cell Syst. 2019 Jul 24;9(1):35-48.e5
pubmed: 31302153
Environ Health Perspect. 2011 Aug;119(8):1142-8
pubmed: 21543282
Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20569-74
pubmed: 24259714
Cell. 2008 Feb 22;132(4):661-80
pubmed: 18295582
Nat Biotechnol. 2008 Mar;26(3):313-5
pubmed: 18278034

Auteurs

Seungmi Ryu (S)

Stem Cell Translation Laboratory (SCTL), Division of Preclinical Innovation (DPI), National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Rockville, MD, USA.

Pei-Hsuan Chu (PH)

Stem Cell Translation Laboratory (SCTL), Division of Preclinical Innovation (DPI), National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Rockville, MD, USA.

Claire Malley (C)

Stem Cell Translation Laboratory (SCTL), Division of Preclinical Innovation (DPI), National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Rockville, MD, USA.

John Braisted (J)

Stem Cell Translation Laboratory (SCTL), Division of Preclinical Innovation (DPI), National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Rockville, MD, USA.

Pinar Ormanoglu (P)

Stem Cell Translation Laboratory (SCTL), Division of Preclinical Innovation (DPI), National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Rockville, MD, USA.

Ruili Huang (R)

Stem Cell Translation Laboratory (SCTL), Division of Preclinical Innovation (DPI), National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Rockville, MD, USA.

Misha Itkin (M)

Stem Cell Translation Laboratory (SCTL), Division of Preclinical Innovation (DPI), National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Rockville, MD, USA.

Zina Itkin (Z)

Stem Cell Translation Laboratory (SCTL), Division of Preclinical Innovation (DPI), National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Rockville, MD, USA.

Paul Shinn (P)

Stem Cell Translation Laboratory (SCTL), Division of Preclinical Innovation (DPI), National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Rockville, MD, USA.

Carleen Klumpp-Thomas (C)

Stem Cell Translation Laboratory (SCTL), Division of Preclinical Innovation (DPI), National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Rockville, MD, USA.

Sam Michael (S)

Stem Cell Translation Laboratory (SCTL), Division of Preclinical Innovation (DPI), National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Rockville, MD, USA.

Carlos A Tristan (CA)

Stem Cell Translation Laboratory (SCTL), Division of Preclinical Innovation (DPI), National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Rockville, MD, USA.

Anton Simeonov (A)

Stem Cell Translation Laboratory (SCTL), Division of Preclinical Innovation (DPI), National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Rockville, MD, USA.

Ilyas Singeç (I)

Stem Cell Translation Laboratory (SCTL), Division of Preclinical Innovation (DPI), National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Rockville, MD, USA. ilyas.singec@nih.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH